The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

In zebrafish, ketamine causes changes a brain circuit involved in "giving up." That may help explain how the drug helps ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

Studies show that antidepressants don’t always work. One psychologist explains how to take control of negative thoughts ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study ...

After six weeks, both the treatment group and the placebo group experienced an average 12.5-point reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS). The drug also fell short in i ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...

Studies show psilocybin from mushrooms could revolutionize depression treatment offering hope to millions who don't respond ...

To treat depression, the tech magnate has said he'd rather use ketamine, a dissociative anesthetic, than traditional antidepressants.

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

Thomas Trutschel / Photothek via Getty Images Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged. The biopharmaceutical firm's navacaprant ...